Predisposition, Genetic Clinical Trial
Official title:
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study
The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test
Status | Not yet recruiting |
Enrollment | 1000 |
Est. completion date | January 31, 2028 |
Est. primary completion date | January 31, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria Group 1- Cancer Predisposition Syndrome: - Age >22 for patients with TP53 germline pathogenic variants, age >35 for all other variants in cancer predisposing genes - Germline genetic testing revealed pathogenic germline variants in cancer predisposing genes (list of genes typically tested listed in pre-screening document) - Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia) Inclusion Criteria Group 2 - Familial Risk: - Age >45 - Adults with family history suggestive of elevated cancer risk as defined by any the criteria below, who do not fall into Group 1: - >1 first or second degree relative on same side of the family with: - Breast, colon, gastric, endometrial, kidney cancer at or before age 50 - Triple negative breast cancer (any age) - Male breast cancer (any age) - Ovarian, pancreatic, sarcoma cancer (any age) - Neuroendocrine cancer or tumors (any age) - Metastatic prostate cancer (any age) - Multiple primary cancers (example bilateral breast cancer) - >2 first or second degree relative on same side of the family (any combination is acceptable) with breast or prostate cancer at any age Exclusion Criteria: - Individuals diagnosed with invasive malignancy within 3 years of enrollment - Have had a blood-based multi-cancer screening test within last year - Individuals with evidence of symptomatic or active cancer requiring active therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is considered acceptable and will not preclude participation) - Individuals in process of being evaluated for clinical suspicion of cancer - Individuals who have undergone a cancer risk-reducing surgery for hereditary cancer risk (e.g., mastectomy). - Individuals with known hematologic precursor disease (e.g. CHIP, MGUS, etc.) - Individuals without English-language proficiency |
Country | Name | City | State |
---|---|---|---|
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cancer Detection Rate | Descriptive statistics will be used to summarize the number and types of cancers diagnosed by GRAIL Galleri MCED testing. | Up to 2 years | |
Secondary | Stage of Invasive Cancer Diagnosis | Descriptive statistics will be used to summarize the stages of invasive cancer that are diagnosed by GRAIL Galleri MCED testing and assessed by medical record review. | Up to 2 years | |
Secondary | Positive Predictive Value At 12 Months | Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results. | At 12 months | |
Secondary | Positive Predictive Value at 24 Months | Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results. | At 24 months | |
Secondary | Time to Diagnostic Resolution | Defined as the time required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. | Calculated from the date of return of screening results (up to 4 weeks from baseline) until up to 24 months post screening | |
Secondary | Test Type Utilization to Diagnostic Resolution | Per participant the count of the number and types of diagnostic tests required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. | Up to 24 months | |
Secondary | Change in Participant Anxiety | Changes in anxiety following the GRAIL Galleri MCED test result and assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Emotional Distress Anxiety - Short Form 6a, which is a 6 item survey that is rated on a 5-point Likert scale with answers ranging from "Never" to "Always". The range of scoring is from 6 to 30 with higher scores indicating greater severity of anxiety. | Up to 24 months | |
Secondary | Change in Participant Health-related Quality of Life | Changes in health-related quality of life following the GRAIL Galleri MCED test result and assessed by PROMIS Scale v1.2 - Global Health, a 10 item survey that is rated on a 5-point Likert scale with answers ranging from "Excellent/Completely/Never/None" to "Poor/Not at all/Always/Very Severe" and includes a pain average question rated on a scale of 0 "No Pain" to 10 "Worst Pain Imaginable." The range of scoring is from 9 to 45 with higher scores indicating higher quality of life. | Up to 24 months | |
Secondary | Cost of Follow-up Testing | Defined as the dollar cost, per participant, of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. | Up to 24 months | |
Secondary | Institutional Reimbursement of Follow-up Testing | Defined as the dollar cost, per participant, of the institutional reimbursement of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03472807 -
EXOme Rare Cancers in Children (EXOCARE)
|
N/A | |
Completed |
NCT04848142 -
Psychosocial Impact of Disclosing Cancer Predisposition Genetic Testing Results During Childhood
|
||
Completed |
NCT03982446 -
Germline Mutations in Pancreatic Adenocarcinoma
|
||
Enrolling by invitation |
NCT04419896 -
The Informed Genetics Annotated Patient Registry
|